Ipafricept - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Drug Profile

Ipafricept - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Alternative Names: Fzd8-Fc; Ipafricept; OMP 54F28

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Class Antineoplastics; Disulfides; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Proteins; Recombinant fusion proteins
  • Mechanism of Action Frizzled 8 receptor modulators; Wnt protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatocellular carcinoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Highest Development Phases

  • Suspended Hepatocellular carcinoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Dec 2017 OncoMed Pharmaceuticals completes a phase I trial for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater, In adults, In the elderly) in USA (IV) (NCT02092363)
  • 01 Jul 2017 OncoMed Pharmaceuticals completes a phase I trial for Hepatocellular carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT02069145)
  • 08 May 2017 OncoMed Pharmaceuticals suspends patient enrolment in a phase I trial for Hepatocellular carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in the phase Ib HER2-negative breast cancer trial (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top